Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 3, 2013, Pages 599-607

  Bonelli, M ^a   Ferner, E ^a   Goschl L ^a   Bluml S ^a   Hladik, A ^a   Karonitsch, T ^a   Kiener, H P ^a   Byrne, R ^a   Niederreiter, B ^a   Steiner, C W ^a   Rath, E ^a   Bergmann, M ^a   Smolen, J S ^a   Scheinecker, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CELL ADHESION; CELL COUNT; CELL FUNCTION; CELL MIGRATION; CELL SPREADING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE ACTIVATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD14; ANTIGENS, CD80; ANTIGENS, CD86; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; CELL MOVEMENT; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; MONOCYTES;

EID: 84874413124     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37787     Document Type: Article

References (23)

1. McInnes IB, Leung BP, Liew FY,. Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res 2000; 2: 374-8.
2. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
3. Appleman LJ, Boussiotis VA,. T cell anergy and costimulation. Immunol Rev 2003; 192: 161-80.
4. Grohmann U, Bianchi R, Orabona C, Fallarino F, Vacca C, Micheletti A, et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol 2003; 171: 2581-7.
5. Munn DH, Sharma MD, Mellor AL,. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172: 4100-10.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
7. Aletaha D, Smolen J,. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl 39: S100-8.
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
9. Pietschmann P, Cush JJ, Lipsky PE, Oppenheimer-Marks N,. Identification of subsets of human T cells capable of enhanced transendothelial migration. J Immunol 1992; 149: 1170-8.
10. Oppenheimer-Marks N, Davis LS, Lipsky PE,. Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell. J Immunol 1990; 145: 140-8.
11. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-71.
12. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN,. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277: 7766-75.
13. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-101.
14. Carman JA, Davis PM, Yang WP, Zhu J, Chang H, He A, et al. Abatacept does not induce direct gene expression changes in antigen-presenting cells. J Clin Immunol 2009; 29: 479-89.
15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
16. Cairns AP, Crockard AD, Bell AL,. The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 2002; 21: 189-92.
17. brightCD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012; 64: 671-7.
18. Nobes CD, Hall A,. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144: 1235-44.
19. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002; 110: 1419-27.
20. Santos LL, Morand EF,. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 2009; 399: 1-7.
21. Schett G,. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 2007; 9: 203.
22. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008; 67: 1603-9.
23. Baliga P, Chavin KD, Qin L, Woodward J, Lin J, Linsley PS, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58: 1082-90.